NEW YORK — Stocks are surging Monday, catapulting Wall Street back to record heights, on a burst of hope following encouraging data about a potential COVID-19 vaccine.
The S&P 500 was 3.3% higher in morning trading after Pfizer said an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19, though that doesn’t mean its release is imminent. The index at the heart of many 401(k) accounts is on track to close at a record for the first time in more than two months.
Financial markets around the world were already climbing before the vaccine data’s release, and Wall Street seemed set to follow on relief that the limbo created by the long, market-bruising battle for the White House was finally clearing. Democrat Joe Biden over the weekend clinched the last of the electoral votes needed to become the next president.
U.S. stock futures, Treasury yields and oil prices burst even higher immediately following the vaccine news. The yield on the 10-year Treasury shot up from 0.81% before the announcement to 0.95%, a very big move for the bond market and one that shows stronger confidence in the economy.
Stocks of companies that most need the economy and the world to return to normal for their profits to heal led the way. A 12.1% surge for Chevron and 11.3% jump for The Walt Disney Co. amid hopes that people will start driving and flying to theme parks again helped drive the Dow Jones Industrial Average to a leap of 1,212 points, or 4.3%, to 29,535, as of 10:35 a.m. Eastern time.
Cruise operators, airlines and mall owners were also among the market’s biggest winners. Carnival surged 36%, though it’s still down by more than half for 2020 so far.
The Big Tech companies that drove the market higher earlier in the pandemic, in large part because they didn’t need a “normal” economy to succeed, were lagging behind. That kept a lid on the gains for the Nasdaq composite, which rose a more modest 1.6%.
If a vaccine for COVID-19 does indeed pan out, analysts say it’s a “game changer” and just what the market had been waiting for. It underscores again how the coronavirus and its effect on the economy are the dominant concerns for investors, much more than who wins what in Washington.
The 90% effectiveness rate for Pfizer’s potential vaccine is what struck Ajay Rajadhyaksha, head of macro research at Barclays.
“If that proves to be correct, it is a significant positive surprise and increases the odds of a quicker return to normalcy,” he said.
Still, analysts caution that several risks remain that could trip up the market’s big recent gains.
Investors are pushing stocks up as they focus on a more encouraging future, but the present is still bleak in many ways. Coronavirus counts continue to rise at troubling rates across much of Europe and the United States, so much that several European governments have brought back restrictions on businesses.
And in Washington, some uncertainties remain that could derail what’s already become a roughly 11% rally for the S&P 500 so far in November. Markets are banking on control of Congress remaining split between Democrats and Republicans, which can keep low tax rates and other pro-business policies the status quo in Washington, but that hinges on the result of run-off elections in Georgia in January.
Potential gridlock also makes any potential rescue package for the economy from Congress likely to be smaller than if Democrats had swept control of all of Washington. President Donald Trump, meanwhile, has refused to concede the election and continues to threaten legal action.
For now, though, euphoria about a possible return to normal is the dominant force across markets, particularly as that layers on top of the tremendous aid for the economy that the Federal Reserve has already put in place.
“Keep in mind that when you remove the virus from the equation, we are set up tremendously well for growth given the unprecedented easy money policies of the Fed,” said Chris Larkin, managing director of trading and investing product at E-Trade Financial.
Last week, the Fed kept short-term interest rates at their record low. Economists expect the central bank to also boost its support for the economy in an attempt to pick up the slack from a hesitant Congress.
Pfizer jumped 7.6% as its announcement indicates the company is on track to file an emergency use application with U.S. regulators later this month.
Benchmark U.S. crude oil surged 9.6% to $40.69 per barrel on expectations that a healthier economy will burn more energy. Brent crude, the international standard, rose 8.3% to $42.74 per barrel.
Gold, meanwhile, fell 4.5% to $1,864.70 per ounce as investors felt less need to crowd into investments considered safe refuges.
Some investors weren’t able to participate immediately, though. Charles Schwab said Monday morning that a technical issue meant clients may have difficulty logging in.
France’s CAC 40 soared 8% and Germany’s DAX returned 5.6%. The FTSE 100 in London jumped 5.4%. Japan’s Nikkei 225 rose 2.1%, South Korea’s Kospi rose 1.3%, Hong Kong’s Hang Seng gained 1.2% and stocks in Shanghai rose 1.9%.
AP Business Writer Yuri Kageyama and AP journalist Alice Fung contributed.
Stan Choe, The Associated Press